Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HBIO Stock Forecast 2026-2027
$6.90
Current Price
$31.10M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to HBIO Price Targets
-13.0%
To High Target of $6.00
-13.0%
To Median Target of $6.00
-13.0%
To Low Target of $6.00
HBIO Price Momentum
+8.3%
1 Week Change
+28.3%
1 Month Change
+115.3%
1 Year Change
+2.8%
Year-to-Date Change
-27.4%
From 52W High of $9.50
+146.3%
From 52W Low of $2.80
📊 TOP ANALYST CALLS
Did HBIO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Harvard Bioscience is one of their latest high-conviction picks.
Latest HBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, HBIO has a neutral consensus with a median price target of $6.00 (ranging from $6.00 to $6.00). The overall analyst rating is Buy (7.0/10). Currently trading at $6.90, the median forecast implies a -13.0% downside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Bruce D. Jackson at Benchmark, projecting a 13.0% downside. Conversely, the most conservative target is provided by Bruce D. Jackson at Benchmark, suggesting a 13.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HBIO Analyst Ratings
1
Buy
1
Hold
0
Sell
HBIO Price Target Range
Low
$6.00
Average
$6.00
High
$6.00
Current: $6.90
Latest HBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 16, 2026 | Benchmark | Bruce D. Jackson | Speculative Buy | Maintains | $6.00 |
| Mar 13, 2026 | Benchmark | Bruce D. Jackson | Speculative Buy | Maintains | $0.60 |
| Sep 10, 2025 | Benchmark | Bruce D. Jackson | Speculative Buy | Maintains | $2.00 |
| May 13, 2025 | Benchmark | Bruce Jackson | Speculative Buy | Maintains | $3.00 |
| Apr 9, 2025 | Keybanc | Paul Knight | Sector Weight | Downgrade | $N/A |
| Apr 8, 2025 | Keybanc | Sector Weight | Downgrade | $N/A | |
| Mar 24, 2025 | Benchmark | Bruce Jackson | Speculative Buy | Maintains | $4.50 |
| Jun 22, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $7.00 |
| Apr 26, 2023 | Keybanc | Paul Knight | Overweight | Maintains | $7.00 |
| Apr 26, 2023 | Benchmark | Bruce Jackson | Buy | Maintains | $7.00 |
| Mar 10, 2023 | Benchmark | Kenneth Bruce | Buy | Reiterates | $4.00 |
| Nov 9, 2022 | Keybanc | Paul Knight | Overweight | Maintains | $5.00 |
| Aug 5, 2022 | Keybanc | Paul Knight | Overweight | Maintains | $7.00 |
| Nov 10, 2020 | KeyBanc | Overweight | Initiates | $N/A | |
| Nov 10, 2020 | Keybanc | Overweight | Initiates | $N/A | |
| Feb 27, 2020 | Benchmark | Bruce Jackson | Speculative Buy | Maintains | $4.00 |
| Nov 17, 2016 | Singular Research | Buy | Initiates | $N/A | |
| Jul 28, 2015 | Benchmark | Buy | Initiates | $N/A | |
| Nov 26, 2013 | Sidoti & Co. | Buy | Upgrade | $N/A |
Harvard Bioscience Inc (HBIO) Competitors
The following stocks are similar to Harvard Bioscience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HBIO
Harvard Bioscience
mkt cap
28.68M
Harvard Bioscience Inc (HBIO) Financial Data
Harvard Bioscience Inc has a market capitalization of $31.10M with a P/E ratio of -5.3x. The company generates $86.55M in trailing twelve-month revenue with a -65.5% profit margin.
Revenue growth is -3.3% quarter-over-quarter, while maintaining an operating margin of +14.0% and return on equity of -147.1%.
Valuation Metrics
Market Cap
$31.10M
Enterprise Value
$66.03M
P/E Ratio
-5.3x
PEG Ratio
0.0x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
-3.3%
Gross Margin
+59.7%
Operating Margin
+14.0%
Net Margin
-65.5%
EPS Growth
-3.3%
Financial Health
Cash/Price Ratio
+27.9%
Current Ratio
2.2x
Debt/Equity
322.4x
ROE
-147.1%
ROA
+0.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Harvard Bioscience Inc (HBIO) Business Model
About Harvard Bioscience Inc
What They Do
Develops life science research technologies and products.
Business Model
Harvard Bioscience generates revenue by developing, manufacturing, and selling life science research instruments and consumables. They cater to a diverse clientele, including academic institutions and biopharmaceutical companies, and market their products under various established brands through multiple channels such as catalogs, websites, and direct sales.
Additional Information
Founded in 1901 and headquartered in Holliston, Massachusetts, the company operates globally with significant operations in North America, Europe, and Asia-Pacific. It maintains manufacturing and R&D facilities in both the United States and Europe, indicating a strong commitment to innovation and support for the global life science research ecosystem.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
330
CEO
Mr. John Duke
Country
United States
IPO Year
2001
Website
www.harvardbioscience.comHarvard Bioscience Inc (HBIO) Latest News & Analysis
Latest News
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
11 days ago
Quick Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO) will report Q1 2026 financial results on May 12, 2026, before market open, followed by a conference call at 8:00 a.m.
Why It Matters
Harvard Bioscience's upcoming financial results and conference call may impact stock performance and investor sentiment, influencing trading decisions and market expectations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Harvard Bioscience, Inc. (HBIO) held its Q4 2025 earnings call, discussing financial results and company performance. Details on revenue and strategic initiatives were covered.
Why It Matters
The Q4 2025 earnings call provides insights into Harvard Bioscience's financial performance and future outlook, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Harvard Bioscience reported Q4 2025 revenues of $23.7M with a gross margin of 59.7%. Full year revenues reached $86.6M. Mark Frost is now permanent CFO, with 2026 guidance indicating revenue growth.
Why It Matters
Harvard Bioscience's strong Q4 revenues and gross margins, along with positive 2026 guidance, indicate growth potential, which can influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Harvard Bioscience Announces Reverse Stock Split
2 months ago
Quick Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO) will implement a 1-for-10 reverse stock split, effective March 16, 2026, as approved by its board of directors.
Why It Matters
The 1-for-10 reverse stock split may enhance Harvard Bioscience's share price, potentially improving market perception and attracting institutional investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO) will participate in KeyBanc Capital Markets' Virtual Healthcare Forum on March 17, 2026, with CEO John Duke and Interim CFO Mark Frost.
Why It Matters
Harvard Bioscience's participation in a key healthcare forum indicates potential visibility and engagement with investors, which could impact stock performance and market sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
2 months ago
Quick Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO) will release Q4 2025 financial results on March 12, 2026, before market opens, followed by a conference call at 8:00 a.m.
Why It Matters
Upcoming financial results and conference call for Harvard Bioscience on March 12, 2026, could significantly influence stock price and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About HBIO Stock
What is Harvard Bioscience Inc's (HBIO) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Harvard Bioscience Inc (HBIO) has a median price target of $6.00. The highest price target is $6.00 and the lowest is $6.00.
Is HBIO stock a good investment in 2026?
According to current analyst ratings, HBIO has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HBIO stock?
Wall Street analysts predict HBIO stock could reach $6.00 in the next 12 months. This represents a -13.0% decrease from the current price of $6.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Harvard Bioscience Inc's business model?
Harvard Bioscience generates revenue by developing, manufacturing, and selling life science research instruments and consumables. They cater to a diverse clientele, including academic institutions and biopharmaceutical companies, and market their products under various established brands through multiple channels such as catalogs, websites, and direct sales.
What is the highest forecasted price for HBIO Harvard Bioscience Inc?
The highest price target for HBIO is $6.00 from Bruce D. Jackson at Benchmark, which represents a -13.0% decrease from the current price of $6.90.
What is the lowest forecasted price for HBIO Harvard Bioscience Inc?
The lowest price target for HBIO is $6.00 from Bruce D. Jackson at Benchmark, which represents a -13.0% decrease from the current price of $6.90.
What is the overall HBIO consensus from analysts for Harvard Bioscience Inc?
The overall analyst consensus for HBIO is neutral. Out of 5 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are HBIO stock price projections?
Stock price projections, including those for Harvard Bioscience Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 8:07 AM UTC